Literature DB >> 27234416

Comparison of 2-Dose and 3-Dose 9-Valent Human Papillomavirus Vaccine Schedules in the United States: A Cost-effectiveness Analysis.

Jean-François Laprise1, Lauri E Markowitz2, Harrell W Chesson2, Mélanie Drolet1, Marc Brisson3.   

Abstract

A recent clinical trial using the 9-valent human papillomavirus virus (HPV) vaccine has shown that antibody responses after 2 doses are noninferior to those after 3 doses, suggesting that 2 and 3 doses may have comparable vaccine efficacy. We used an individual-based transmission-dynamic model to compare the population-level effectiveness and cost-effectiveness of 2- and 3-dose schedules of 9-valent HPV vaccine in the United States. Our model predicts that if 2 doses of 9-valent vaccine protect for ≥20 years, the additional benefits of a 3-dose schedule are small as compared to those of 2-dose schedules, and 2-dose schedules are likely much more cost-efficient than 3-dose schedules.
© The Author 2016. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail journals.permissions@oup.com.

Entities:  

Keywords:  HPV vaccination; cost-effectiveness; human papillomavirus (HPV); transmission-dynamic modeling

Mesh：

Substances：

Year:  2016        PMID： 27234416      PMCID： PMC4978371          DOI： 10.1093/infdis/jiw227

Source DB:  PubMed          Journal:  J Infect Dis        ISSN： 0022-1899            Impact factor:   5.226


  13 in total

1.  2012 updated consensus guidelines for the management of abnormal cervical cancer screening tests and cancer precursors.

Authors:  L Stewart Massad; Mark H Einstein; Warner K Huh; Hormuzd A Katki; Walter K Kinney; Mark Schiffman; Diane Solomon; Nicolas Wentzensen; Herschel W Lawson
Journal:  Obstet Gynecol       Date:  2013-04       Impact factor: 7.661

2.  Health and Economic Impact of Switching from a 4-Valent to a 9-Valent HPV Vaccination Program in the United States.

Authors:  Marc Brisson; Jean-François Laprise; Harrell W Chesson; Mélanie Drolet; Talía Malagón; Marie-Claude Boily; Lauri E Markowitz
Journal:  J Natl Cancer Inst       Date:  2015-10-04       Impact factor: 13.506

3.  Efficacy of fewer than three doses of an HPV-16/18 AS04-adjuvanted vaccine: combined analysis of data from the Costa Rica Vaccine and PATRICIA Trials.

Authors:  Aimée R Kreimer; Frank Struyf; Maria Rowena Del Rosario-Raymundo; Allan Hildesheim; S Rachel Skinner; Sholom Wacholder; Suzanne M Garland; Rolando Herrero; Marie-Pierre David; Cosette M Wheeler; Paula González; Silvia Jiménez; Douglas R Lowy; Ligia A Pinto; Caroline Porras; Ana Cecilia Rodriguez; Mahboobeh Safaeian; Mark Schiffman; John T Schiller; John Schussler; Mark E Sherman; F Xavier Bosch; Xavier Castellsague; Archana Chatterjee; Song-Nan Chow; Dominique Descamps; Francisco Diaz-Mitoma; Gary Dubin; Maria Julieta Germar; Diane M Harper; David J M Lewis; Genara Limson; Paulo Naud; Klaus Peters; Willy A J Poppe; Brian Ramjattan; Barbara Romanowski; Jorge Salmeron; Tino F Schwarz; Julio C Teixeira; Wiebren A A Tjalma
Journal:  Lancet Oncol       Date:  2015-06-09       Impact factor: 41.316

4.  Comparing the cost-effectiveness of two- and three-dose schedules of human papillomavirus vaccination: a transmission-dynamic modelling study.

Authors:  Jean-François Laprise; Mélanie Drolet; Marie-Claude Boily; Mark Jit; Chantal Sauvageau; Eduardo L Franco; Philippe Lemieux-Mellouki; Talía Malagón; Marc Brisson
Journal:  Vaccine       Date:  2014-08-12       Impact factor: 3.641

5.  A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women.

Authors:  Elmar A Joura; Anna R Giuliano; Ole-Erik Iversen; Celine Bouchard; Constance Mao; Jesper Mehlsen; Edson D Moreira; Yuen Ngan; Lone Kjeld Petersen; Eduardo Lazcano-Ponce; Punnee Pitisuttithum; Jaime Alberto Restrepo; Gavin Stuart; Linn Woelber; Yuh Cheng Yang; Jack Cuzick; Suzanne M Garland; Warner Huh; Susanne K Kjaer; Oliver M Bautista; Ivan S F Chan; Joshua Chen; Richard Gesser; Erin Moeller; Michael Ritter; Scott Vuocolo; Alain Luxembourg
Journal:  N Engl J Med       Date:  2015-02-19       Impact factor: 91.245

6.  Immunogenicity of 2 doses of HPV vaccine in younger adolescents vs 3 doses in young women: a randomized clinical trial.

Authors:  Simon R M Dobson; Shelly McNeil; Marc Dionne; Meena Dawar; Gina Ogilvie; Mel Krajden; Chantal Sauvageau; David W Scheifele; Tobias R Kollmann; Scott A Halperin; Joanne M Langley; Julie A Bettinger; Joel Singer; Deborah Money; Dianne Miller; Monika Naus; Fawziah Marra; Eric Young
Journal:  JAMA       Date:  2013-05-01       Impact factor: 56.272

7.  Use of 9-valent human papillomavirus (HPV) vaccine: updated HPV vaccination recommendations of the advisory committee on immunization practices.

Authors:  Emiko Petrosky; Joseph A Bocchini; Susan Hariri; Harrell Chesson; C Robinette Curtis; Mona Saraiya; Elizabeth R Unger; Lauri E Markowitz
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2015-03-27       Impact factor: 17.586

8.  Comparison of two dose and three dose human papillomavirus vaccine schedules: cost effectiveness analysis based on transmission model.

Authors:  Mark Jit; Marc Brisson; Jean-François Laprise; Yoon Hong Choi
Journal:  BMJ       Date:  2015-01-06

9.  Sustained immunogenicity of the HPV-16/18 AS04-adjuvanted vaccine administered as a two-dose schedule in adolescent girls: Five-year clinical data and modeling predictions from a randomized study.

Authors:  Barbara Romanowski; Tino F Schwarz; Linda Ferguson; Klaus Peters; Marc Dionne; Ulrich Behre; Karin Schulze; Peter Hillemanns; Pemmaraju Suryakiran; Florence Thomas; Frank Struyf
Journal:  Hum Vaccin Immunother       Date:  2015-07-15       Impact factor: 3.452

10.  National, Regional, State, and Selected Local Area Vaccination Coverage Among Adolescents Aged 13-17 Years--United States, 2014.

Authors:  Sarah Reagan-Steiner; David Yankey; Jenny Jeyarajah; Laurie D Elam-Evans; James A Singleton; C Robinette Curtis; Jessica MacNeil; Lauri E Markowitz; Shannon Stokley
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2015-07-31       Impact factor: 17.586
View more
  11 in total

Review 1.  Present challenges in cervical cancer prevention: Answers from cost-effectiveness analyses.

Authors:  Mireia Diaz; Silvia de Sanjosé; F Xavier Bosch; Laia Bruni
Journal:  Rep Pract Oncol Radiother       Date:  2018-04-26

2.  Durability of Protection Afforded by Fewer Doses of the HPV16/18 Vaccine: The CVT Trial.

Authors:  Mahboobeh Safaeian; Joshua N Sampson; Yuanji Pan; Carolina Porras; Troy J Kemp; Rolando Herrero; Wim Quint; Leen Jan van Doorn; John Schussler; Douglas R Lowy; John Schiller; Mark T Schiffman; Ana Cecilia Rodriguez; Mitchell H Gail; Allan Hildesheim; Paula Gonzalez; Ligia A Pinto; Aimée R Kreimer
Journal:  J Natl Cancer Inst       Date:  2018-02-01       Impact factor: 13.506

3.  Review of the economic evidence presented to the United States Advisory Committee on Immunization Practices, 2012-2016.

Authors:  Jamison Pike; Andrew J Leidner; Jessica R MacNeil; Amanda C Cohn
Journal:  Vaccine       Date:  2018-11-23       Impact factor: 3.641

4.  Modeling of US Human Papillomavirus (HPV) Seroprevalence by Age and Sexual Behavior Indicates an Increasing Trend of HPV Infection Following the Sexual Revolution.

Authors:  Marc D Ryser; Anne Rositch; Patti E Gravitt
Journal:  J Infect Dis       Date:  2017-09-01       Impact factor: 5.226

5.  Effectiveness and Cost-Effectiveness of Human Papillomavirus Vaccination Through Age 45 Years in the United States.

Authors:  Jean-François Laprise; Harrell W Chesson; Lauri E Markowitz; Mélanie Drolet; Dave Martin; Élodie Bénard; Marc Brisson
Journal:  Ann Intern Med       Date:  2019-12-10       Impact factor: 25.391

6.  Missed opportunities for HPV immunization among young adult women.

Authors:  Carlos R Oliveira; Robert M Rock; Eugene D Shapiro; Xiao Xu; Lisbet Lundsberg; Liye B Zhang; Aileen Gariepy; Jessica L Illuzzi; Sangini S Sheth
Journal:  Am J Obstet Gynecol       Date:  2017-12-06       Impact factor: 10.693

7.  Health and economic benefits of single-dose HPV vaccination in a Gavi-eligible country.

Authors:  Emily A Burger; Nicole G Campos; Stephen Sy; Catherine Regan; Jane J Kim
Journal:  Vaccine       Date:  2018-05-26       Impact factor: 3.641

8.  The cost-effectiveness of controlling cervical cancer using a new 9-valent human papillomavirus vaccine among school-aged girls in Australia.

Authors:  Rashidul Alam Mahumud; Khorshed Alam; Jeff Dunn; Jeff Gow
Journal:  PLoS One       Date:  2019-10-09       Impact factor: 3.240

9.  Median Age at HPV Infection Among Women in the United States: A Model-Based Analysis Informed by Real-world Data.

Authors:  Vimalanand S Prabhu; Craig S Roberts; Smita Kothari; Linda Niccolai
Journal:  Open Forum Infect Dis       Date:  2021-03-12       Impact factor: 3.835

10.  Optimal human papillomavirus vaccination strategies to prevent cervical cancer in low-income and middle-income countries in the context of limited resources: a mathematical modelling analysis.

Authors:  Mélanie Drolet; Jean-François Laprise; Dave Martin; Mark Jit; Élodie Bénard; Guillaume Gingras; Marie-Claude Boily; Michel Alary; Iacopo Baussano; Raymond Hutubessy; Marc Brisson
Journal:  Lancet Infect Dis       Date:  2021-07-07       Impact factor: 25.071
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.